Trial Profile
A phase I, open label dose escalation study of the VEGF-C human monoclonal antibody VGX-100 administered by intravenous infusion alone and co-administered with bevacizumab in adult patients with advanced or metastatic solid tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; VGX 100 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Circadian Technologies; Opthea
- 16 Sep 2020 Status changed from active, no longer recruiting to completed.
- 21 Jul 2017 Planned End Date changed from 1 Jun 2017 to 1 Nov 2017.
- 21 Jul 2017 Planned primary completion date changed from 1 Apr 2017 to 1 Sep 2017.